Effects of Liposomal Bupivacaine for Superficial Parasternial Intercostal Plane Block on Postoperative Stress and Analgesia in Patients Undergoing Median Sternotomy: A Prospective, Randomized, Double-Blind Trial Authors: Wen Yu, Yundie Li, Aiping Wei, Shibiao Chen, Yang Zhang Published: 2026 ABSTRACT AbstractBackgroundLiposomal bupivacaine may provide prolonged postoperative analgesia, but its efficacy in median sternotomy remains underexplored. This study evaluated whether liposomal bupivacaine for superficial parasternal intercostal plane (SPIP) block improves postoperative analgesia and reduces surgical stress in patients undergoing median sternotomy.MethodsIn this prospective, randomized, double-blind controlled trial, 44 patients undergoing elective median sternotomy under cardiopulmonary bypass were randomized to receive SPIP block with either liposomal bupivacaine or ropivacaine. Primary outcomes were visual analog scale (VAS) pain scores within 72 h postoperatively and serum levels of stress markers, including angiotensin II (Ang-II) and interleukin-6 (IL-6). Secondary outcomes included patient-controlled intravenous analgesia boluses, postoperative nausea and vomiting, extubation time, intensive care unit stay, Quality of Recovery-15 (QoR-15) scores, and complications.ResultsCompared with the ropivacaine group, the liposomal bupivacaine group showed significantly lower VAS pain scores from 18 to 72 h postoperatively (P < 0.05). Although Ang-II and IL-6 levels increased postoperatively in both groups, concentrations were significantly lower in the liposomal bupivacaine group (P < 0.01). Patients receiving liposomal bupivacaine required fewer analgesic boluses, had shorter intensive care unit stays, faster postoperative recovery, lower incidence of postoperative nausea and vomiting, and significantly improved QoR-15 scores (all P < 0.05). No significant differences were observed in extubation time, hospital stay, or hospitalization costs. No block-related complications were observed.ConclusionLiposomal bupivacaine for SPIP block improved analgesia up to 72 hours after surgery, may attenuate the surgical stress response, and could promote early recovery in patients undergoing median sternotomy under cardiopulmonary bypass.Trial RegistrationChinese Clinical Trial Registry (ChiCTR2400091199).Keywords: liposomal bupivacaine, superficial parasternal intercostal plane block, postoperative analgesia, stress response, median sternotomy Introduction A continual rise has been observed in the number of patients undergoing cardiac surgery under cardiopulmonary bypass, driven by the increasing prevalence of cardiovascular diseases such as coronary artery and valvular heart disease within an aging population.1,2 Although significant progress has been made in minimally invasive cardiac surgery and robot-assisted techniques,3,4 median sternotomy with cardiopulmonary bypass remains the most commonly performed procedure to date. This reality stems from a combination of factors, including economic constraints, steep technical learning curves, and disparities in healthcare resource allocation.5 Therefore, postoperative pain management must be prioritized by the clinical care team. Severe acute pain after surgery not impedes recovery but may also progress to chronic pain,6,7 adversely affecting long-term quality of life and functional outcomes in patients.8 Research indicates that patients undergoing median sternotomy with cardiopulmonary bypass are exposed to multiple stressors—including sternotomy, extracorporeal circulation, myocardial ischemia-reperfusion injury, severe postoperative pain, and prolonged mechanical ventilation—all of which can trigger a substantial stress response.9,10 While a moderate stress response activates protective physiological mechanisms, excessive activation leads to persistent hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system.11–13 This results in exaggerated release of cortisol and catecholamines, contributing to hemodynamic instability, glucose metabolism dysregulation, and immunosuppression. Furthermore, excessive stress promotes a massive release of proinflammatory cytokines—such as IL-6 and TNF-α14,15—triggering a systemic inflammatory response that exacerbates tissue damage and compromises organ function. In addition, activation of the renin–angiotensin system, particularly elevated Angiotensin II levels, represents a key component of neuroendocrine stress during surgery, with recent clinical evidence linking perioperative Ang-II dynamics to myocardial injury in surgical patients.16 Postoperative pain management represents a cornerstone of enhanced recovery after surgery (ERAS) protocols.17 Regional nerve blocks are highly recommended due to their technical simplicity and demonstrated ability to reduce opioid consumption. Among these techniques, thoracic paravertebral block (TPVB), erector spinae plane block (ESPB), and pectoral nerve (PECS) blocks have been applied for thoracic and cardiac analgesia.18–20 However, deeper approaches such as TPVB are technically demanding and carry inherent risks, including pleural injury, neuraxial spread, or vascular puncture,21 which are particularly concerning in anticoagulated cardiac surgical patients. Superficial parasternal intercostal plane (SPIP) block has emerged as a promising alternative because it is located between the pectoralis major and internal intercostal muscles,22 allowing ease of ultrasound visualization and a superior safety profile. Recent studies confirm that SPIP block effectively targets the anterior cutaneous branches of the intercostal nerves. This significantly reduces postoperative pain scores following median sternotomy.23 In this context, the clinical utility of conventional local anesthetics such as ropivacaine is limited by their short duration of action24,25 often necessitating supplemental intravenous analgesia via pump infusion, which diminishes their overall benefit. Liposomal bupivacaine is a multivesicular liposome formulation of bupivacaine designed to provide prolonged local anesthetic release over an extended postoperative period. Its multivesicular liposomal delivery system enables gradual bupivacaine diffusion from lipid vesicles, thereby maintaining therapeutic tissue concentrations while reducing rapid systemic absorption and peak plasma exposure.26,27 This sustained pharmacokinetic profile may prolong peripheral nerve blockade, attenuate nociceptive signaling, reduce central sensitization, and subsequently decrease postoperative opioid requirements. In addition, prolonged analgesia may help mitigate excessive neuroendocrine and inflammatory stress activation following major surgery.28. Studies have shown that a single administration of liposomal bupivacaine for local infiltration can deliver effective analgesia for up to 72 hours, with a favorable safety profile and minimal systemic toxicity, establishing it as an ideal option for localized postoperative pain management.29,30 This formulation has been widely adopted for pain control following total knee arthroplasty (TKA), where it has shown significant advantages in reducing opioid requirements, lowering pain scores, and decreasing overall medical costs.31 Furthermore, Louis et al32 compared liposomal bupivacaine with standard bupivacaine for intercostal nerve block in patients undergoing thoracoscopic surgery and found that the liposomal bupivacaine group required significantly less opioid within the first 24 hours, with a 42% reduction in total in-hospital opioid use. Similarly, Corsini et al33 reported that intercostal nerve block with liposomal bupivacaine significantly reduced the incidence of pulmonary complications in patients undergoing lung resection surgery. Median sternotomy under cardiopulmonary bypass is associated with substantial tissue trauma and a pronounced stress response. Although the analgesic benefits of liposomal bupivacaine have been well-established in various postoperative settings, its efficacy in major cardiac surgeries characterized by severe trauma and intense stress remains underexplored. In particular, its modulatory role in mitigating acute postoperative pain and the subsequent stress response has not been clearly elucidated. Therefore, this study aimed to investigate whether liposomal bupivacaine administered via a SPIP block improves postoperative analgesia and attenuates surgical stress response in patients undergoing median sternotomy, providing a clinical foundation for evidence-based analgesic strategies in cardiac surgery. Methods Study Design and Setting The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (Chairperson: Dr. Zhang Wei) on June 5, 2023 and was registered with the Chinese Clinical Trial Registry on October 7, 2023 (Registration No.: ChiCTR2400091199). This study was conducted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines and the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to surgery. Participants Between September 2024 and January 2025, patients aged 20 to 70 years, with an American Society of Anesthesiologists (ASA) physical status of II–III, body mass index (BMI) between 19.0 and 26.0 kg/m2, cardiac function class II–III, and left ventricular ejection fraction (LVEF) > 40%, who were scheduled to undergo elective cardiac surgery via median sternotomy under general anesthesia, were enrolled. Exclusion criteria included a history of allergic diseases or known allergy to local anesthetics; skin infection or lesions in the area of the block; coagulation disorders; concomitant coronary artery disease; requirement for intra-aortic balloon pump support; congestive heart failure; hepatic or renal failure; history of substance abuse; chronic pain; psychiatric disorders; emergency or redo surgery; and patient refusal to participate. Participants were also excluded in cases of severe local anesthetic systemic toxicity, drug-related adverse events requiring emergency intervention, inadequate sensory block coverage as assessed by pinprick test, insufficient analgesic efficacy, or voluntary withdrawal from the study. Randomization and Blinding Eligible patients were randomly assigned in a 1:1 ratio to receive either ropivacaine or liposomal bupivacaine based on a computer-generated randomization sequence. To maintain strict blinding during preparation and administration, an independent anesthesiologist assistant prepared the study medications in a separate room. Both drugs were prepared as identical 20 mL transparent solutions and drawn into identical syringes labeled only with a study ID. These pre-filled syringes were handed to the performing anesthesiologist, who remained blinded to treatment allocation. Allocation was concealed in sequentially numbered, sealed envelopes, which were opened only by the preparing assistant. Because the anesthesiologist, intraoperative team, and outcome assessors were not involved in drug preparation and the syringes were visually indistinguishable, complete blinding was maintained throughout the trial. Anesthetic Management Anesthesia was administered according to a standardized protocol. Upon arrival in the operating room, standard monitoring—including electrocardiography, non-invasive blood pressure, and pulse oximetry—was established, and intravenous access was secured. Intravenous midazolam (1–2 mg) and sufentanil (5 μg) were administered, followed by local infiltration with 1% lidocaine (1 mL) to facilitate placement of an invasive radial arterial catheter. Induction was achieved with intravenous flurbiprofen axetil (50 mg), etomidate (0.2 mg/kg), cisatracurium besylate (0.2 mg/kg), and sufentanil (1 μg/kg). Anesthesia was maintained using a continuous infusion of propofol (6–8 mg/kg/h) and remifentanil (4–6 μg/kg/h), with supplemental doses of sufentanil and cisatracurium besylate administered as needed based on surgical stimulation. The depth of anesthesia was monitored using the bispectral index (BIS), which was maintained between 30 and 55. Systemic heparinization was performed prior to cardiopulmonary bypass (CPB), which was initiated once the activated clotting time (ACT) exceeded 480 seconds. During the rewarming phase, intravenous infusions of dopamine (6 μg/kg/min) and nitroglycerin (2 μg/kg/min) were initiated to enhance myocardial contractility and reduce systemic vascular resistance. Doses were titrated individually according to the hemodynamic response. Arterial blood gas analyses were performed periodically throughout the procedure. Acid-base balance and electrolyte abnormalities were promptly corrected to maintain intraoperative homeostasis. Superficial Parasternal Intercostal Plane Block After entering the operating room, standard vital sign monitoring was established, and oxygen was administered via face mask. The anterior chest wall was thoroughly disinfected, and skin integrity was confirmed. Cutaneous sensation was assessed bilaterally using an ice test prior to block performance. With the patient in the supine position, a high-frequency linear ultrasound transducer (Wisonic DW-M9, Shenzhen Wisonic Medical Technology Co., Ltd., China) was positioned longitudinally approximately 2 cm parasternal, aligned parallel to the sternum. Under real-time ultrasound guidance, the pectoralis major muscle, internal intercostal muscles, costal cartilage, and deeper pleural and lung structures were clearly identified (Figure 1). Following local infiltration with 1 mL of 1% lidocaine at the needle insertion point between the third and fourth ribs, a block needle was advanced using an in-plane technique. Under continuous sonographic visualization, the needle tip was first directed superiorly toward the second rib while depositing local anesthetic, then redirected inferiorly toward the sixth rib, with continuous hydrodissection to confirm appropriate tissue plane expansion. The needle tip was positioned between the posterior aspect of the pectoralis major muscle and the anterior aspect of the internal intercostal muscle. After negative aspiration for air or blood, a test injection of 2 mL normal saline was administered to confirm proper fascial plane spread. A total volume of 20 mL of the study medication was administered, divided into 10 mL for each side. For the intervention group, this equated to a total dose of 133 mg of 0.665% liposomal bupivacaine (20 mL:266 mg, manufactured by Jiangsu Hengrui Pharmaceuticals Co., Ltd., China, H20223899); for the control group, this equated to a total dose of 75 mg of 0.375% ropivacaine (10 mL:100 mg, manufactured by AstraZeneca AB, Sweden, approval number H20140763). The injections were performed incrementally with needle tip movement to ensure uniform distribution between the second and sixth ribs bilaterally. Spread of the local anesthetic was monitored in real time using ultrasonography. The same procedure was repeated on the contralateral side. Thirty minutes after completing bilateral blocks, sensory blockade was assessed bilaterally using the ice test. Patients with inadequate block coverage, defined as absent or incomplete loss of cold sensation in the target dermatomes (T2–T6), were excluded from the study. Sononatomy for ultrasound-guided superficial parasternal intercostal plane block. 1. Pectoralis major; 2. Internal intercostal muscle (Intercostales interni); 3. Transversus thoracis; 4. Internal thoracic vessels; 5. Pleura; 6. Sternum. Outcomes The primary outcomes of this study were postoperative pain intensity at rest and during deep inspiration within 72 hours and stress markers including Ang-II and IL-6 measured at 24 and 72 hours postoperatively. Secondary outcomes included the number of effective patient-controlled intravenous analgesia (PCIA) boluses, hemodynamic stability, time to first extubation, time to first flatus, length of ICU stay, and Quality of Recovery-15 (QoR-15) scores assessed at 24, 48, and 72 hours postoperatively. Additionally, safety outcomes encompassed the incidence of postoperative nausea and vomiting, pruritus, respiratory depression, and complications related to nerve block or anesthesia, as well as total hospital length of stay and total hospitalization costs. Postoperative pain was evaluated using a Visual Analog Scale (VAS, 0 = “no pain”, 10 = “worst pain imaginable”), which was a 10‑cm horizontal line. Patients were asked to mark the point that best represented their pain intensity. And pain assessments were performed when patients regained sufficient consciousness to understand and cooperate with evaluation. For patients who remained intubated but were conscious and able to communicate nonverbally, VAS scoring was completed with assistance from trained investigators using visual guidance. Postoperative hospital stay duration was calculated from postoperative day 1 until hospital discharge after the patient met recovery and discharge criteria. Hospitalization expenses were defined as the total in-hospital costs incurred from admission until discharge, including perioperative management, surgical treatment, postoperative recovery, medications, nursing care, laboratory and imaging examinations, and ICU-related expenses. The QoR-15 score, which assesses five dimensions (pain, physical comfort, physical independence, psychological state, and emotional support) through 15 items, was summed to yield a total score ranging from 0 (extremely poor recovery) to 150 (excellent recovery). Postoperative Pain Management and ERAS Protocol After surgery, hemodynamically stable patients were transferred to the cardiothoracic ICU. A standardized PCIA protocol was implemented, consisting of sufentanil 100 μg, flurbiprofen axetil 100 mg, and ondansetron 24 mg diluted to 100 mL with normal saline. The PCIA pump was programmed with a background infusion rate of 0.5 mL/h, a bolus dose of 2 mL, and a lockout interval of 30 minutes. Patients were instructed to self-administer a bolus when their resting VAS score exceeded 4. Analgesic efficacy was regularly assessed, and the background infusion rate was adjusted if necessary. Rescue analgesia was provided under physician supervision in cases of inadequate pain control. All patients were managed under an ERAS protocol, which included: early mobilization (sitting, standing, and walking) to prevent pulmonary complications; early enteral nutrition to facilitate gastrointestinal recovery; minimized use of morphine and other opioids to reduce postoperative nausea and vomiting; early removal of drains and urinary catheters to promote mobility; and aggressive airway management including pulmonary toileting and incentive spirometry to support pulmonary function. Measurement of Serum Ang-II and IL-6 Levels via ELISA Peripheral venous blood samples (5 mL) were collected from each patient at predefined time points (T0: preoperatively; T1: 24 h postoperatively; T2: 72 h postoperatively). Samples were placed in EDTA-containing tubes, gently inverted, and centrifuged at 3000 × g for 10 min at 4°C. The supernatant plasma was aliquoted and stored at −80°C until analysis. Commercially available human-specific ELISA kits were used to quantify Ang-II (E-EL-H0326c; Elabscience Biotechnology Co., Ltd, Wuhan, China) and IL-6 (EK0410; Boster Biological Technology, Wuhan, China) levels according to the manufacturer’s instructions. All samples were measured in duplicate. The detailed procedure was as follows: 1)Reagent Preparation: All kits and samples were removed from −80°C storage and allowed to equilibrate to room temperature (25 ± 2°C) for 20 min before use. The microplate reader was preheated for 15 min. Reagent Preparation: All kits and samples were removed from −80°C storage and allowed to equilibrate to room temperature (25 ± 2°C) for 20 min before use. The microplate reader was preheated for 15 min. 2)Wash Buffer Preparation: The concentrated wash buffer was diluted 1:24 (v/v) with distilled water. If crystals were present, the solution was warmed in a 40°C water bath until completely dissolved. Wash Buffer Preparation: The concentrated wash buffer was diluted 1:24 (v/v) with distilled water. If crystals were present, the solution was warmed in a 40°C water bath until completely dissolved. 3)Standard Curve Preparation: The lyophilized standard was reconstituted by adding 1.0 mL of standard diluent to the vial, followed by centrifugation at 10,000 × g for 60s. The vial was incubated at room temperature for 10 min and gently inverted several times to ensure complete dissolution, producing a stock solution of 2000 pg/mL. A series of double-dilutions were performed to generate standard points covering the expected concentration range. Standard Curve Preparation: The lyophilized standard was reconstituted by adding 1.0 mL of standard diluent to the vial, followed by centrifugation at 10,000 × g for 60s. The vial was incubated at room temperature for 10 min and gently inverted several times to ensure complete dissolution, producing a stock solution of 2000 pg/mL. A series of double-dilutions were performed to generate standard points covering the expected concentration range. 4)Assay Procedure: 100 µL of each standard, control, and sample were added to appropriate wells, covered with an adhesive strip, and incubated for 2 h at room temperature. The liquid was aspirated, and each well was washed four times with 300 µL wash buffer. Then, 100 µL of detection antibody was added to each well and incubated for 1 h at room temperature. After washing, 100 µL of horseradish peroxidase (HRP)-conjugated streptavidin was added and incubated for 30 min. Following a final wash, 100 µL of tetramethylbenzidine (TMB) substrate was added and incubated for 15 min in the dark. The reaction was stopped with 50 µL stop solution. Assay Procedure: 100 µL of each standard, control, and sample were added to appropriate wells, covered with an adhesive strip, and incubated for 2 h at room temperature. The liquid was aspirated, and each well was washed four times with 300 µL wash buffer. Then, 100 µL of detection antibody was added to each well and incubated for 1 h at room temperature. After washing, 100 µL of horseradish peroxidase (HRP)-conjugated streptavidin was added and incubated for 30 min. Following a final wash, 100 µL of tetramethylbenzidine (TMB) substrate was added and incubated for 15 min in the dark. The reaction was stopped with 50 µL stop solution. 5)Measurement and Calculation: The optical density (OD) of each well was immediately measured at 450 nm using a microplate reader. A standard curve was constructed by plotting the OD values against the known standard concentrations, and a four-parameter logistic (4-PL) regression model was applied to calculate analyte concentrations in the samples. Measurement and Calculation: The optical density (OD) of each well was immediately measured at 450 nm using a microplate reader. A standard curve was constructed by plotting the OD values against the known standard concentrations, and a four-parameter logistic (4-PL) regression model was applied to calculate analyte concentrations in the samples. Sample Size Calculation The sample size was determined based on the results of a preliminary experiment, with the Visual Analog Scale (VAS) score at 72 hours postoperatively as the primary outcome. A power analysis was performed using SPSS (version 16.0). The pre-trial results indicated a standard deviation of VAS scores of 1.8 across both groups, with an expected reduction of 1–2 points in VAS scores after intervention. With a two-sided Type I error probability (α) of 0.05 and a statistical power (1–β) of 0.90, the estimated required sample size was 20 participants per group. To account for potential participant drop-out and withdrawal, a total sample size of 44 patients (22 per group) was ultimately enrolled. Statistical Analysis All data were managed in accordance with requirements for randomized controlled trial (RCT) data. Initial data were stored using a standardized protocol. Upon study completion, blinding was lifted, and data were entered into the database as numerical or categorical variables. All analyses were conducted using SPSS for Windows version 27.0 (IBM Corp., Armonk, NY, USA). The normality of continuous variables was assessed using the Shapiro–Wilk test. Normally distributed data are presented as mean ± standard deviation and were compared between groups using the independent samples t-test. Non-normally distributed data are expressed as median (interquartile range) and analyzed with the Mann–Whitney U-test. Categorical variables are summarized as counts (percentages) and compared using the chi-square test or Fisher’s exact test, as appropriate. A two-sided p-value of less than 0.05 was considered statistically significant. Results A total of 63 patients were assessed for eligibility. Among them, 19 individuals were excluded from the study. Eight patients did not meet the inclusion criteria, 5 whose surgical approach was changed to minimally invasive surgery and 3 underwent rescheduling of their surgical procedures. Additionally, 10 patients declined to participate in the trial. One further patient was excluded due to being transferred to another hospital. Thus, 44 patients were randomized equally into the ropivacaine group and the liposomal bupivacaine group. One participant in the ropivacaine group was excluded due to postoperative bleeding that required re-sternotomy. Consequently, 43 patients were included in the final analysis. The flow of participants through the trial, based on the CONSORT guidelines (Figure 2). All randomized patients successfully received the designated nerve block intervention. No statistically significant differences were observed between the two groups in terms of demographic characteristics such as age, sex, BMI, ASA physical status, or total operative time (Table 1). CONSORT Flow Diagram of Participant Enrollment, Allocation, and Follow-up. Table 1Baseline Demographic and Perioperative CharacteristicsBupivacaine Liposome (n=22)Ropivacaine (n=21)PAge (years)48.36±12.4949.76±11.900.709BMI (kg/m2)22.76±1.8822.65±1.960.856Gender0.887 Man1211 Women1010Physical status class (II/III)0.996 II22 III1615Heart function grade of NYHA0.658 II1311 III910Cardiac bypass time (min)96.4±22.4695.32±21.690.556Surgery time (min)244.50±31.45236.43±26.170.367Intraoperative sufentanil consumption (ug)124.32±19.74128.81±21.560.624Intraoperative remifentanil consumption (mg)3.12±0.813.22±0.650.656 Baseline Demographic and Perioperative Characteristics No significant differences in heart rate (HR) or mean arterial pressure (MAP) were observed between the two groups from anesthesia induction to the end of surgery (T1 to T4). At 24 hours postoperatively (T5), the mean HR in the liposomal bupivacaine group was approximately 10 beats per minute lower than that in the control group. By 72 hours after surgery (T6), although both groups showed a significant decrease in HR and MAP compared to values at the end of surgery (T4), patients receiving liposomal bupivacaine exhibited HR and MAP levels that returned nearly to preinduction baseline (T1), demonstrating superior hemodynamic stability compared to the ropivacaine group (Table 2). Table 2Intraoperative Hemodynamic Fluctuations and Postoperative Changes in Hormone LevelsBupivacaine Liposome (n=22)Ropivacaine (n=21)PHR T182.73 ± 5.0980.66 ± 5.360.204 T284.27 ± 4.9782.69 ± 5.300.314 T385.23 ± 5.0785.30 ± 5.060.968 T497.82 ± 4.9797.68 ± 5.410.929 T587.36±7.3398.10±7.19P<0.01 T676.68±5.4786.33±5.35P<0.01MAP T182.63±4.9981.23±5.060.367 T285.37±4.6584.05±4.780.364 T386.77±4.8887.53±4.800.610 T499.14±4.7899.13±5.310.998 T584.24±7.9891.81±4.72P<0.01 T682.41±4.8586.72±5.120.007Ang-II (ng/L) Pre-operation53.11±6.6352.93±5.240.924 Postoperation-24h61.40±6.0780.28±7.05P<0.01 Postoperation-48h54.78±6.7659.55±3.660.007IL-6 (ng/L) Pre-operation20.56±2.4320.82±2.340.369 Postoperation-24h30.37±3.6240.92±7.00P<0.01 Postoperation-48h26.29±1.7432.75±2.62P<0.01Notes: T1: Pre-induction, T2: Incision, T3: Sternotomy, T4: Surgery end, T5: Postop 24h, T6: Postop 72h.Abbreviations: HR, heart rate; MAP, mean arterial pressure. Intraoperative Hemodynamic Fluctuations and Postoperative Changes in Hormone Levels Notes: T1: Pre-induction, T2: Incision, T3: Sternotomy, T4: Surgery end, T5: Postop 24h, T6: Postop 72h. Abbreviations: HR, heart rate; MAP, mean arterial pressure. Changes in hormonal levels provided an objective reflection of surgical stress. Perioperative levels of angiotensin II (Ang-II) and interleukin-6 (IL-6) were measured. At 24 hours postoperatively, Ang-II levels increased by 15.6% in the liposomal bupivacaine group, compared to a markedly higher increase of 51.6% in the ropivacaine group. Similarly, IL-6 levels were significantly higher in the ropivacaine group than in the liposomal bupivacaine group. By 72 hours after surgery, both Ang-II and IL-6 levels had declined relative to the 24-hour measurements, but the liposomal bupivacaine group showed values much closer to preoperative baseline. Comparison of postoperative pain scores between the two groups revealed that patients in the liposomal bupivacaine group had significantly lower VAS scores at 18, 24, 36, 48, and 72 hours after surgery compared to those in the ropivacaine group (P < 0.05), both at rest and during deep inspiration (Table 3). Meanwhile, no significant differences were observed in VAS scores at 6 and 12 hours postoperatively (P > 0.05). Furthermore, during the first and second 24-hour periods after surgery, the number of PCIA boluses used was significantly higher in the ropivacaine group than in the liposomal bupivacaine group. Table 3Postoperative Pain Score and the Frequency of PCAIBupivacaine Liposome (n=22)Ropivacaine (n=21)PVisual Analog Scale (rest) 6h1.13±0.421.18±0.400.692 12h1.38±0.361.42±0.290.712 18h1.67±0.392.34±0.42P<0.01 24h2.15±0.382.93±0.42P<0.01 36h2.52±0.353.63±0.43P<0.01 48h2.92±0.494.20±0.46P<0.01 72h3.40±0.494.44±0.52P<0.01Visual Analog Scale (apneustic) 6h1.30±0.431.35±0.410.709 12h1.70±0.401.83±0.340.262 18h2.25±0.392.88±0.42P<0.01 24h2.68±0.453.60±0.40P<0.01 36h3.33±0.334.30±0.52P<0.01 48h3.73±0.314.75±0.45P<0.01 72h4.54±0.485.19±0.56P<0.01PCIA Postoperation 24h1.59±1.765.62±1.72P<0.01 Postoperation 24h–48h8.41±1.9215.67±4.24P<0.01 Postoperative Pain Score and the Frequency of PCAI No block-related complications (eg, vascular puncture, pneumothorax, local anesthetic systemic toxicity) occurred in either group. With regard to postoperative adverse events, nausea was reported in 6 patients (27.3%) in the liposomal bupivacaine group, compared with 16 patients (72.7%) in the ropivacaine group. No instances of pruritus, vomiting, or respiratory depression were observed in either group. Patients in the liposomal bupivacaine group exhibited significantly shorter durations of ICU stay, time to first ambulation, and time to first flatus compared to those in the ropivacaine group. Although extubation time was numerically shorter in the liposomal bupivacaine group, the difference did not reach statistical significance. Furthermore, quality of recovery, as assessed by the QoR-15 score, was significantly improved in the liposomal bupivacaine group on each of the first three postoperative days compared to the control group (Table 4). Table 4Adverse Reactions and Postoperative RecoveryBupivacaine Liposome (n=22)Ropivacaine (n=21)PSide effects of nerve blockage Vascular puncture0 (0)0 (0)NA Pleural puncture0 (0)0 (0)NA Local anesthetics toxicity0 (0)0 (0NA Upper limb motor blockade0 (0)0 (0)NAPost-operative side effects Postoperative nausea6 (27.27)16 (72.72)0.003 Episodes of vomiting0 (0)1 (2)NA Pruritus0 (0)0 (0)NA Respiratory depression0 (0)0 (0)NAExtubation time (h)6.05±1.136.48±1.540.3Length of stay in the ICU (h)32.77±3.4241.19±2.91P<0.01Time to first flatus (h)15.41±1.9717.48±1.690.001The time of first getting out of bed (h)77.45±3.0892.00±2.28P<0.01Postoperative hospital stay duration (h)9.95±1.4010.14±1.110.628Hospitalization expenses (¥)14.66±1.7514.63±2.150.972QoR-15 score D186.50±4.6578.95±3.43<0.01 D2109.36±5.30104.67±5.18<0.01 D3128.45±6.16115.71±5.26<0.01 Adverse Reactions and Postoperative Recovery Discussion In this prospective, randomized, double-blind, controlled trial, we systematically evaluated the effects of liposomal bupivacaine administered via a superficial parasternal intercostal plane block on postoperative analgesia and surgical stress response in patients undergoing median sternotomy with cardiopulmonary bypass. The results suggested that liposomal bupivacaine was associated with lower VAS pain scores during the 72-hour postoperative period and a trend toward reduced demand for patient-controlled analgesia compared to conventional ropivacaine. Moreover, it appeared to attenuate the surgical stress response, which may contribute to improved hemodynamic stability, enhanced recovery quality, and potentially faster overall rehabilitation. There is broad consensus that cardiac surgery is evolving toward minimally invasive techniques.34 However, complex procedures such as valve replacement, coronary artery bypass grafting, and major vascular surgery still predominantly rely on conventional median sternotomy.35–37 Median sternotomy remains highly invasive, often requires cardiopulmonary bypass support, and induces a substantial surgical stress response.38,39 The ensuing severe and persistent postoperative pain can lead to prolonged hospitalization, impaired recovery quality, and increased healthcare costs.17,40 Consequently, there is growing emphasis on optimizing postoperative analgesia and stress modulation in cardiac surgical patients. Traditional analgesic protocols relying solely on opioids are increasingly being superseded by multimodal analgesia strategies due to well-documented adverse effects such as respiratory depression, nausea and vomiting, and potential for dependence. Currently, regional nerve blocks combined with nonsteroidal anti-inflammatory drugs or low-dose opioids have emerged as a superior analgesic approach.41 Substantial evidence42–46 indicates that regional nerve blocks provide effective analgesia and significantly reduce opioid consumption in patients undergoing cardiac surgery. Nevertheless, a major limitation persists: the short duration of action of conventional local anesthetics such as ropivacaine, which typically provides less than 8 hours of analgesia, is insufficient to cover the 72-hour acute postoperative pain period. Although continuous catheter-based paravertebral blockade has been attempted to extend analgesia, this technique may increase the risk of bleeding and hematoma formation in cardiac surgery patients who often experience postoperative coagulopathy. In this context, liposomal bupivacaine has emerged as a novel long-acting local anesthetic formulation. Utilizing a multivesicular liposomal drug delivery system that enables sustained release of the agent, a single administration can provide prolonged effective analgesia,47 thereby offering a promising solution to overcome the limitations of medium-to long-term pain management after cardiac surgery. The results of this study demonstrate that liposomal bupivacaine significantly extended the duration of effective postoperative analgesia. During the 18- to 72-hour postoperative period, VAS scores at rest and during deep inspiration were significantly lower in the liposomal bupivacaine group than in the ropivacaine group, accompanied by a notable reduction in patient-controlled analgesia boluses. These results demonstrate that the unique multivesicular liposomal sustained-release properties of liposomal bupivacaine successfully address the clinical limitation of conventional local anesthetics, whose effect typically lasts less than 8 hours, thereby extending the duration of effective analgesia to approximately 72 hours. It is noteworthy that no significant difference in analgesic effect was observed between the two groups within the first 12 hours after surgery, a finding consistent with previous reports on ropivacaine used in transversus thoracic muscle plane block,48 indicating comparable efficacy between the two agents during the initial period of block onset. Modulating the postoperative stress response is a critical factor influencing recovery quality in patients undergoing cardiac surgery.49 The present study revealed the regulatory effect of liposomal bupivacaine on this response. Although levels of stress markers (Ang-II and IL-6) peaked at 24 hours postoperatively in both groups, the peak concentrations and values on postoperative day 2 were significantly lower in the liposomal bupivacaine group than in the ropivacaine group. Liposomal bupivacaine likely attenuates neuroendocrine and inflammatory stress by continuously blocking nociceptive input, thereby suppressing excessive activation of the hypothalamic-pituitary-adrenal axis and inhibiting the inflammatory cascade. Correspondingly, patients receiving liposomal bupivacaine also demonstrated greater stability in heart rate and mean arterial pressure at 24 and 72 hours after surgery, indicating improved hemodynamic protective effects. Within the enhanced recovery after surgery (ERAS) framework, liposomal bupivacaine administration was associated with multiple clinical benefits. Patients in this group demonstrated significantly shorter ICU stays, reduced time to first flatus, earlier ambulation, a lower incidence of postoperative nausea and vomiting, and significantly higher scores on the QoR-15 questionnaire. These improvements are closely linked to superior analgesia and a attenuated surgical stress response, suggesting that liposomal bupivacaine enhances overall recovery through optimized pain management. Although no significant differences were observed between groups in total hospital length of stay or overall costs, this lack of significance may be related to the limited sample size. Future studies with larger cohorts are warranted to further evaluate its potential health economic advantages. While previous studies have confirmed that the transversus thoracic muscle plane block can provide effective analgesia for anterior thoracic wall surgery,50,51 this technique carries a higher risk of pneumothorax and vascular injury due to its deeper location and proximity to the internal thoracic artery. In contrast, the superficial parasternal intercostal plane block targets the same neural structures and provides comparable postoperative analgesic efficacy, yet its more superficial location and absence of major vascular structures in the needle trajectory enhance its safety profile. In the present study, ultrasound-guided PIFP block was performed without any instances of local anesthetic systemic toxicity or block-related complications, supporting its safety for use in cardiac surgery. This study has several limitations. First, pain following median sternotomy originates from diverse sources, including the sternotomy incision itself, postoperatively placed chest tubes, potential intraoperative rib fractures or nerve injuries, and lower limb incision sites in cases where coronary artery bypass grafting was performed. The regional nerve block technique employed in this study primarily targeted thoracic wall pain pathways and may not have comprehensively addressed all pain sources. Future studies could consider combining multimodal superficial parasternal intercostal plane block with targeted local incision infiltration to improve perioperative comfort. Second, the assessment of postoperative inflammatory levels was limited to specific time points, which may not fully capture the dynamic changes in cytokine profiles or their association with long-term patient outcomes. Subsequent research should incorporate more frequent blood sampling time points to better elucidate the relationship between the postoperative inflammatory response and clinical prognosis. While we reported a 100% success rate with no patients excluded due to inadequate block coverage, this may not fully reflect the real-world success rate or inherent risks of the technique. Since all blocks were performed by a single senior anesthesiologist with extensive expertise in nerve blocks, the observed superior efficacy and low complication profile might be biased. And our findings may not provide a completely objective comparison with other regional anesthesia methods. Furthermore, this was a single-center study with a relatively small sample size, which limits the generalizability of our conclusions. Therefore, larger multi-center cohort studies are warranted to further evaluate the potential advantages and economic benefits of this nerve block in the broader context of cardiac surgery. Conclusion In summary, liposomal bupivacaine administered via a superficial parasternal intercostal plane block provides effective analgesia for up to 72 hours, significantly attenuates the postoperative stress response, improves hemodynamic stability, and facilitates recovery in patients undergoing median sternotomy, with a favorable safety profile. This technique represents a promising component of multimodal analgesic strategies in cardiac surgery, warranting further investigation in larger trials to validate its long-term benefits and health economic advantages. Acknowledgments The authors sincerely thank the entire anesthesiology team at the First Affiliated Hospital of Nanchang University, as well as all the patients who participated in this study for their invaluable contributions. Funding Statement This work was supported by grants from the National Natural Science Foundation of China (82060023 and 82360385); the Natural Science Foundation of Jiangxi Province (20253BAC280077); Basic Research on Special Central Venous Catheters (1210102006); The First Affiliated Hospital of Nanchang University Clinical Research Cultivation Project: Multimodal Analgesia Clinical Study of Ultra-long-acting Local Anesthetics Combined with a New Generation of Opioid Drugs (YFYLCYJPY202405). Data Sharing Statement Data are available from the corresponding author, Shibiao Chen (chenlaoshi1111@163.com), Yang Zhang (mzzhangyang@126.com), upon reasonable request. Ethics Approval and Informed Consent This study was registered at the Chinese Clinical Trial Registry (ChiCTR2400091199) on 10/07/2023, and the Ethics Committee of the First Affiliated Hospital of Nanchang University approved the study on 06/05/2023. All the participants provided written informed consent. Consent for Publication Individual consent was obtained from all participating patients. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors reports no conflicts of interest in this work. References Associated Data Data Availability Statement Data are available from the corresponding author, Shibiao Chen (chenlaoshi1111@163.com), Yang Zhang (mzzhangyang@126.com), upon reasonable request.